NYSE:SNN Smith & Nephew SNATS (SNN) Stock Price, News & Analysis $30.67 +0.45 (+1.49%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Smith & Nephew SNATS Stock (NYSE:SNN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Smith & Nephew SNATS alerts:Sign Up Key Stats Today's Range$30.43▼$30.6950-Day Range$25.71▼$30.3052-Week Range$23.69▼$31.72Volume626,237 shsAverage Volume816,835 shsMarket Capitalization$13.43 billionP/E Ratio14.20Dividend Yield2.90%Price Target$28.00Consensus RatingHold Company OverviewSmith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.Read More… Smith & Nephew SNATS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreSNN MarketRank™: Smith & Nephew SNATS scored higher than 71% of companies evaluated by MarketBeat, and ranked 298th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingSmith & Nephew SNATS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageSmith & Nephew SNATS has only been the subject of 3 research reports in the past 90 days.Read more about Smith & Nephew SNATS's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth18.34% Earnings GrowthEarnings for Smith & Nephew SNATS are expected to grow by 18.34% in the coming year, from $1.69 to $2.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Smith & Nephew SNATS is 14.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Smith & Nephew SNATS is 14.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.46.Price to Earnings Growth RatioSmith & Nephew SNATS has a PEG Ratio of 0.93. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioSmith & Nephew SNATS has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Smith & Nephew SNATS's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.57% of the float of Smith & Nephew SNATS has been sold short.Short Interest Ratio / Days to CoverSmith & Nephew SNATS has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Smith & Nephew SNATS has recently decreased by 14.78%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldSmith & Nephew SNATS pays a meaningful dividend of 2.96%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSmith & Nephew SNATS does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Smith & Nephew SNATS is 41.20%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 44.50% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.Read more about Smith & Nephew SNATS's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.57% of the float of Smith & Nephew SNATS has been sold short.Short Interest Ratio / Days to CoverSmith & Nephew SNATS has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Smith & Nephew SNATS has recently decreased by 14.78%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.94 News SentimentSmith & Nephew SNATS has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Smith & Nephew SNATS this week, compared to 4 articles on an average week.Search Interest2 people have searched for SNN on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Smith & Nephew SNATS to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Smith & Nephew SNATS is held by insiders.Percentage Held by InstitutionsOnly 25.64% of the stock of Smith & Nephew SNATS is held by institutions.Read more about Smith & Nephew SNATS's insider trading history. Receive SNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Smith & Nephew SNATS and its competitors with MarketBeat's FREE daily newsletter. Email Address SNN Stock News HeadlinesSmith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fracturesJune 24, 2025 | globenewswire.comAjay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy OfficerJune 23, 2025 | globenewswire.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.June 30 at 2:00 AM | Porter & Company (Ad)Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UKJune 18, 2025 | globenewswire.comNew medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatilityJune 9, 2025 | globenewswire.comSmith & Nephew (SN) Receives a Buy from CitiJune 7, 2025 | theglobeandmail.comSmith & Nephew SNATS, Inc. Common Stock (SNN)May 31, 2025 | nasdaq.comSmith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of DefenseMay 27, 2025 | globenewswire.comSee More Headlines SNN Stock Analysis - Frequently Asked Questions How have SNN shares performed this year? Smith & Nephew SNATS's stock was trading at $24.58 on January 1st, 2025. Since then, SNN shares have increased by 24.8% and is now trading at $30.67. View the best growth stocks for 2025 here. How were Smith & Nephew SNATS's earnings last quarter? Smith & Nephew SNATS, Inc. (NYSE:SNN) posted its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.59. How do I buy shares of Smith & Nephew SNATS? Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Smith & Nephew SNATS own? Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew SNATS investors own include JPMorgan Chase & Co. (JPM), Johnson & Johnson (JNJ), PepsiCo (PEP), Taiwan Semiconductor Manufacturing (TSM), McDonald's (MCD), Sanofi (SNY) and Alibaba Group (BABA). Company Calendar Last Earnings11/17/2014Record date for 5/28 Dividend3/28/2025Ex-Dividend for 5/28 Dividend3/28/2025Dividend Payable5/28/2025Today6/30/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNYSE:SNN CIK845982 Webwww.smith-nephew.com Phone441923477100Fax44-20-7930-3353Employees17,349Year Founded1856Price Target and Rating Average Stock Price Target$28.00 High Stock Price Target$28.00 Low Stock Price Target$28.00 Potential Upside/Downside-8.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio14.10 Forward P/E Ratio18.03 P/E Growth0.93Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.62 Current Ratio2.89 Quick Ratio1.33 Sales & Book Value Annual Sales$5.81 billion Price / Sales2.30 Cash Flow$3.18 per share Price / Cash Flow9.57 Book Value$12.04 per share Price / Book2.53Miscellaneous Outstanding Shares437,970,000Free Float433,593,000Market Cap$13.34 billion OptionableOptionable Beta0.68 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:SNN) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Smith & Nephew SNATS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Smith & Nephew SNATS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.